Edinburgh, Scotland (August 20, 2024) - Blackford, the pioneering strategic AI platform and solutions provider, and CureMetrix®, a leading innovator in AI-driven mammography solutions, today announced a commercial partnership to bring cmAngio® to healthcare professionals via the Blackford Platform.
Blackford’s tried-and-tested platform provides healthcare providers access to an extensive portfolio of more than 135 AI solutions designed to elevate clinical accuracy and efficiency and improve patient outcomes. By integrating CureMetrix’ advanced technology into the Blackford Platform, Blackford can offer healthcare providers powerful tools to support detection and localization of breast arterial calcifications (BAC) without requiring additional screening.
"We are thrilled to be partnering with CureMetrix and to integrate their innovative mammography solutions into the Blackford portfolio." says Ben Panter, Founder and CEO of Blackford. "This partnership enables us to further our support for preventive health and incidental findings and to further our mission to improve the health of patients and populations around the world."
cmAngio is the first-of-its-kind*, FDA-cleared, proprietary, artificial intelligence (AI) based software intended to detect at the study and breast level, the presence or absence of Breast Arterial Calcifications (BAC), an incidental finding in both Full Field Digital Mammogram (FFDM) and Digital Breast Tomosynthesis (DBT) screening mammograms. This enables radiologists to use existing screening mammograms as a 2-for-1 exam to identify women with BAC and refer them for further evaluation as necessary. Additionally, cmAngio highlights BAC segments on thumbnail images of the screening mammograms for precise localization.
Kevin Harris, President of CureMetrix noted that “Launching cmAngio on the Blackford Platform represents an opportunity to bring our novel, one-of-a-kind, FDA cleared software to a wider network of healthcare organizations. Screening for Breast Arterial Calcifications is a critical component in a comprehensive women’s health program. We are excited to work with the Blackford team to help positively impact healthcare and identify patients with calcifications to further our mission to improve women’s health outcomes.”